temporary platelet increase. Other means of minimizing risk for bleeding remain important and include use of aminocaproic acid and HLA matched platelets, prevention of hypertension while thrombocytopenic, pre-transplant testing for platelet reactive antibodies so HLA matched platelets may be obtained sooner, and choice of transplant conditioning regimen.
Introduction: Asperillus thyroiditis (AT) has been considered for long time a postmortem diagnosis in immunocompromised patients. Disseminated disease is seen in the majority of patients. Diagnosis of AT during life needs high index of suspicion. Objective: We describe an adolescent HSCT recipient with disseminated aspergillus infection who presented initially with painful neck swelling and found to have AT. Case Report: History: A 15 years-old male with history of Acute Myeloid Leukemia and MUD HSCT who presented to our institution with painful neck swelling, sore throat, red/ brown sputum and worsening respiratory distress for 2 days. Mom had of Hashimoto's thyroiditis. Physical Exam: His had initial hypotension, tachycardia, tachypnea and fine hand tremors. He had a neck swelling that was moving up and down on swallowing with tenderness but no nodules on palpation. Laboratory: His evaluation showed thrombocytopenia, normal WBC counts with neutrophil predominance, hypokalemia, transaminitis, direct hyperbilirubinemia, elevated Free T4 and very low TSH. Fine needle aspirate (FNA) of the thyroid and the sputum showed yeast on KOH. Imaging: Thyroid US with diffuse heterogeneous enlargement. CT Chest showed moderate to large areas of pulmonary consolidation bilaterally, with areas of cavitation. Clinical course: He was started on broad-spectrum antibiotics and antifungals. His respiratory and mental status got worse one day after admission needing transfer of care to the Pediatric ICU. His FNA of the thyroid grew Aspergillus Fumigatus. MRI brain showed numerous rounded lesions consistent with disseminated fungal disease, most likely Aspergillus. Family chose to continue with palliative care only with DNR/DNI having his disseminated disease and critical condition. Discussion: Our patient had evidence of disseminated invasive aspergillosis involving thyroid, lungs and brain. Initially he had presumed infectious thyroiditis based on his clinical examination and laboratory values that were confirmed to be AT. Thyroid-related symptomatology can be occasionally seen on presentation. Although viral sub-acute and bacterial thyroiditis is more common than fungal one, but in immunocompromised patients AT has to be considered early on. Thyroid US guided FNA cytology and culture is considered to be a well-tolerated procedure that frequently utilized to diagnose AT successfully. Any delay in the management may significantly affect the outcomes where thyroid FNA can play a critical role in the early diagnosis of AT. Conclusion: The diagnosis of Aspergillus Thyroiditis requires a high index of suspicion and it can be the initial presentation of disseminated invasive aspergillosis. Further studies are needed to evaluate the benefits of combined antifungals and address the management of thyroid hormone dysregulation.
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Low Dose Defibrotide for Management of Hepatic VenoOcclusive Disease Bhausaheb Bagal, Aliya Choughale, Navin Navin Khattry. Tata Memorial Centre, BMT Unit, ACTREC, Navi Mumbai, India Background and objective: Hepatic veno-occlusive disease (VOD) is recognized as one of the common and serious regimen-related toxicity seen after hematopoietic stem cell transplantation (HSCT). VOD develops in 10% to 60% of patients after HSCT, and ranges in severity from mild to a severe syndrome associated with multiorgan failure and death. Defibrotide (DF) is the only drug found to be effective in the management of VOD. A randomised study showed that 25 mg/kg/d was equally effective with lesser toxicity compared to 40mg/kg/d. DF is prohibitively expensive and availability is scarce in our country. Methods: Two hundred and ninety nine patients (166 autologous and 133 allogeneic; 210 male and 89 female) who underwent HSCT between November 2007 and June 2013 were included in this study. All patients received ursodeoxycolic acid as prophylaxis. The diagnosis and severity of VOD was defined according to Seattle criterion. Risk of development of severe VOD was estimated by Bearman model. Patients who developed VOD were initially treated with frusemide and analgesia. Patients not responding to above measures in 36-48 hours were given DF. Results: Seven patients (2.3%) were diagnosed with VOD at a median of days +14 post transplant (range 11 to 16 days). All 7 patients were classified as having moderate VOD. All Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210 S190
